[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.249.135. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1988

Local Tolerance and Activity of MK-927, a Novel Topical Carbonic Anhydrase Inhibitor

Author Affiliations

From the Clinical Research Department, Merck Sharp & Dohme Research Laboratories, West Point, Pa (Dr Lippa); the Department of Ophthalmology, Technical University of Munich (Drs von Denffer and Hofmann); and the Clinical Pharmacology Department, Merck Sharp & Dohme Research Laboratories, Rahway, NJ (Dr Brunner-Ferber).

Arch Ophthalmol. 1988;106(12):1694-1696. doi:10.1001/archopht.1988.01060140866029
Abstract

• A three-dose, randomized, double-masked, parallel, placebo-controlled ocular tolerance study was undertaken in 12 healthy, normal volunteers with the water-soluble, topical carbonic anhydrase inhibitor MK-927. To our knowledge, this constitutes the first administration of MK-927 to humans. Ten subjects received three drops of 2% MK-927 ophthalmic solution and two subjects received three drops of placebo (vehicle) in one randomly selected eye. Local tolerance of 2% MK-927 was acceptable and supports further clinical trials in patients. Significant intraocular pressure (IOP)-lowering activity was noted when comparing IOP four hours after first dose with that 20 hours predose in the treated eye of subjects receiving MK-927 (mean percent change in IOP, −29.7%; mean change in IOP, −4.6 mm Hg) as opposed to the same comparison for the contralateral, untreated eye (−7.2% and −1.3 mm Hg, respectively). In the two subjects treated with placebo, IOP-lowering activity was not seen in either the placebo-treated eye (−0.4%) or the contralateral, untreated eye (+3.1%).

References
1.
Maren TH, Jankowska L, Sanyal G, et al:  The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion . Exp Eye Res 1983;36:457-480.Article
2.
Stein A, Pinke R, Krupin T, et al:  The effect of topically administered carbonic anhydrase inhibitors on aqueous humor dynamics in rabbits . Am J Ophthalmol 1983;95:222-228.Article
3.
Lewis RA, Schoenwald RD, Eller MG, et al:  Ethoxzolamide and analogue gel: A topical carbonic anhydrase inhibitor . Arch Ophthalmol 1984;102:1821-1824.Article
4.
Bar-Ilan A, Pessah NI, Maren TH:  The effects of carbonic anhydrase inhibitors on aqueous humor chemistry and dynamics . Invest Ophthalmol Vis Sci 1984;25:1198-1205.
5.
Sugrue MF, Gautheron P, Schmitt C, et al:  On the pharmacology of L-645,151: A topically effective ocular hypotensive carbonic anhydrase inhibitor . J Pharmacol Exp Ther 1985;232:534-540.
6.
Bar-Ilan A, Pessah NI, Maren TH:  Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor L-645,151 . J Ocular Pharmacol 1986;2:109-120.Article
7.
Duffel MW, Ing IS, Segarra TM, et al:  N-substituted sulfonamide carbonic anhydrase inhibitors with topical effects on intraocular pressure . J Med Chem 1986;29:1488-1494.Article
8.
Maren TH, Bar-Ilan A, Caster KC, et al:  Ocular pharmacology of methazolamide analogs: Distribution in the eye and effects on pressure after topical application . J Pharmacol Exp Ther 1987;241:56-63.
9.
Maren TH:  Carbonic anhydrase: General perspectives and advances in glaucoma research . Drug Dev Res 1987;10:255-276.Article
10.
Ponticello GS, Freedman MB, Habecker CN, et al:  Thienothiopyran-2-sulfonamides: A novel class of water-soluble carbonic anhydrase inhibitors . J Med Chem 1987;30:591-597.Article
11.
Lewis RA, Schoenwald RD, Barfknecht CF, et al:  Aminozolamide gel: A trial of a topical carbonic anhydrase inhibitor in ocular hypertension . Arch Ophthalmol 1986;104:842-844.Article
12.
Kalina PH, Shetlar DJ, Lewis RA, et al:  6-Amino-2-benzothiazolesulfonamide: The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal eye . Ophthalmology 1988;95:772-777.Article
13.
Werner EB, Gerber DS, Yolanda JY:  Effect of a topical carbonic anhydrase inhibitor, 6-hydroxybenzo[b]thiophene-2-sulfonamide, on intraocular pressure in normotensive subjects . Can J Ophthalmol 1987;22:316-319.
14.
Maren TH, Bar-Ilan A:  Effect of 6-OH benzo[b]thiophene-2-sulfonamide, a new topical carbonic anhydrase (CA) inhibitor on intraocular pressure in rabbits . Invest Ophthalmol Vis Sci 1987;28( (suppl) ):268.
15.
Sugrue MF, Gautheron P, Grove J, et al:  MK-927: A topically effective ocular hypotensive carbonic anhydrase (CA) inhibitor in rabbits . Invest Ophthalmol Vis Sci 1988;29( (suppl) ):81.
16.
Maren TH, Bar-Ilan A:  Ocular pharmacology and hypotensive activity of a topically active carbonic anydrase (CA) inhibitor, a 4-alkylaminothienothiopyran-2-sulfonamide, MK-927 . Invest Ophthalmol Vis Sci 1988;29( (suppl) ):16.
17.
Wang RF, Serle JB, Podos SM, et al:  The ocular hypotensive effect of the topical carbonic anhydrase (CA) inhibitor MK-927 in glaucomatous monkeys . Invest Ophthalmol Vis Sci 1988;29( (suppl) ):16.
18.
Wistrand PJ, Garg LC:  Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes . Invest Ophthalmol Vis Sci 1979;18:802-806.
19.
Maren TH:  The relation between enzyme inhibition and physiological response in the carbonic anhydrase system . J Pharmacol Exp Ther 1963;139:140-153.
20.
Berson FG, Epstein DL:  Separate and combined effects of timolol maleate and acetazolamide in open-angle glaucoma . Am J Ophthalmol 1981;92:788-791.
21.
Kass MA, Korey M, Gordon M, et al:  Timolol and acetazolamide: A study of concurrent administration . Arch Ophthalmol 1982;100:941-942.Article
22.
Dailey RA, Brubaker RF, Bourne WM:  The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects . Am J Ophthalmol 1982;93:232-237.
23.
Hennekes R, Pfeiffer N, Lippa EA, et al:  MK-927: An active topical carbonic anydrase inhibitor in patients . Invest Ophthalmol Vis Sci 1988;29( (suppl) ):82.
24.
Lippa EA, Hofmann HM, Feicht B, et al: MK-927: A topically effective carbonic anhydrase inhibitor in patients. Read before the Third Congress of the European Glaucoma Society, Estoril, Portugal, May 24, 1988.
×